Avacopan

Drug Profile

Avacopan

Alternative Names: CCX 168

Latest Information Update: 15 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ChemoCentryx
  • Developer ChemoCentryx; Mario Negri Institute for Pharmacological Research
  • Class Anti-inflammatories; Cyclopentanes; Piperidines; Small molecules
  • Mechanism of Action Complement C5a receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glomerulonephritis; Anti-neutrophil cytoplasmic antibody-associated vasculitis; Haemolytic uraemic syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Anti-neutrophil cytoplasmic antibody-associated vasculitis
  • Phase II Haemolytic uraemic syndrome; IgA nephropathy
  • Phase I Autoimmune disorders
  • Clinical Phase Unknown Glomerulonephritis

Most Recent Events

  • 09 Jun 2017 Avacopan licensed to Kissei Pharmaceuticals in Japan
  • 06 Jun 2017 Safety and efficacy results from a phase II clinical trial in IgA nephropathy released by ChemoCentryx
  • 23 May 2017 Avacopan receives Orphan Drug status for Glomerulonephritis in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top